Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP Young
NCT05726227Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Primary completion
- Oct 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Body Mass Index at 104 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05726227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726227.